These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling. Huang H; Hu J; Maryam A; Huang Q; Zhang Y; Ramakrishnan S; Li J; Ma H; Ma VWS; Cheuk W; So GYK; Wang W; Cho WCS; Zhang L; Chan KM; Wang X; Chin YR Nat Commun; 2021 Apr; 12(1):2242. PubMed ID: 33854062 [TBL] [Abstract][Full Text] [Related]
3. Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis. Franco HL; Nagari A; Malladi VS; Li W; Xi Y; Richardson D; Allton KL; Tanaka K; Li J; Murakami S; Keyomarsi K; Bedford MT; Shi X; Li W; Barton MC; Dent SYR; Kraus WL Genome Res; 2018 Feb; 28(2):159-170. PubMed ID: 29273624 [TBL] [Abstract][Full Text] [Related]
4. Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer. Ropri AS; DeVaux RS; Eng J; Chittur SV; Herschkowitz JI Breast Cancer Res; 2021 Oct; 23(1):101. PubMed ID: 34717732 [TBL] [Abstract][Full Text] [Related]
6. The hyper-activation of transcriptional enhancers in breast cancer. Li QL; Wang DY; Ju LG; Yao J; Gao C; Lei PJ; Li LY; Zhao XL; Wu M Clin Epigenetics; 2019 Mar; 11(1):48. PubMed ID: 30867030 [TBL] [Abstract][Full Text] [Related]
7. TWEAK/Fn14 signalling driven super-enhancer reprogramming promotes pro-metastatic metabolic rewiring in triple-negative breast cancer. Sim N; Carter JM; Deka K; Tan BKT; Sim Y; Tan SM; Li Y Nat Commun; 2024 Jul; 15(1):5638. PubMed ID: 38965263 [TBL] [Abstract][Full Text] [Related]
8. TAF Family Proteins and MEF2C Are Essential for Epstein-Barr Virus Super-Enhancer Activity. Wang C; Jiang S; Zhang L; Li D; Liang J; Narita Y; Hou I; Zhong Q; Gewurz BE; Teng M; Zhao B J Virol; 2019 Aug; 93(16):. PubMed ID: 31167905 [TBL] [Abstract][Full Text] [Related]
9. Genomic regulation of invasion by STAT3 in triple negative breast cancer. McDaniel JM; Varley KE; Gertz J; Savic DS; Roberts BS; Bailey SK; Shevde LA; Ramaker RC; Lasseigne BN; Kirby MK; Newberry KM; Partridge EC; Jones AL; Boone B; Levy SE; Oliver PG; Sexton KC; Grizzle WE; Forero A; Buchsbaum DJ; Cooper SJ; Myers RM Oncotarget; 2017 Jan; 8(5):8226-8238. PubMed ID: 28030809 [TBL] [Abstract][Full Text] [Related]
10. Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors. Wang C; Zhang L; Ke L; Ding W; Jiang S; Li D; Narita Y; Hou I; Liang J; Li S; Xiao H; Gottwein E; Kaye KM; Teng M; Zhao B Nat Commun; 2020 Dec; 11(1):6318. PubMed ID: 33298918 [TBL] [Abstract][Full Text] [Related]
11. CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression. Lewis MW; King CM; Wisniewska K; Regner MJ; Coffey A; Kelly MR; Mendez-Giraldez R; Davis ES; Phanstiel DH; Franco HL Cancer Res; 2024 Nov; 84(21):3684-3700. PubMed ID: 39186674 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel. Guo P; Yang J; Huang J; Auguste DT; Moses MA Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18295-18303. PubMed ID: 31451668 [TBL] [Abstract][Full Text] [Related]
13. Yao X; Tan J; Lim KJ; Koh J; Ooi WF; Li Z; Huang D; Xing M; Chan YS; Qu JZ; Tay ST; Wijaya G; Lam YN; Hong JH; Lee-Lim AP; Guan P; Ng MSW; He CZ; Lin JS; Nandi T; Qamra A; Xu C; Myint SS; Davies JOJ; Goh JY; Loh G; Tan BC; Rozen SG; Yu Q; Tan IBH; Cheng CWS; Li S; Chang KTE; Tan PH; Silver DL; Lezhava A; Steger G; Hughes JR; Teh BT; Tan P Cancer Discov; 2017 Nov; 7(11):1284-1305. PubMed ID: 28893800 [TBL] [Abstract][Full Text] [Related]
14. NSMCE2, a novel super-enhancer-regulated gene, is linked to poor prognosis and therapy resistance in breast cancer. Di Benedetto C; Oh J; Choudhery Z; Shi W; Valdes G; Betancur P BMC Cancer; 2022 Oct; 22(1):1056. PubMed ID: 36224576 [TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas genome editing in triple negative breast cancer: Current situation and future directions. Fu L; Li Z; Ren Y; Yu H; Liu B; Qiu Y Biochem Pharmacol; 2023 Mar; 209():115449. PubMed ID: 36754153 [TBL] [Abstract][Full Text] [Related]
16. Oncogenic transcription factors instruct promoter-enhancer hubs in individual triple negative breast cancer cells. Zhao J; Zhou Y; Tzelepis I; Burget NG; Shi J; Faryabi RB Sci Adv; 2024 Aug; 10(32):eadl4043. PubMed ID: 39110799 [TBL] [Abstract][Full Text] [Related]
17. Circular RNA circ-ZEB1 acts as an oncogene in triple negative breast cancer via sponging miR-448. Pei X; Zhang Y; Wang X; Xue B; Sun M; Li H Int J Biochem Cell Biol; 2020 Sep; 126():105798. PubMed ID: 32629026 [TBL] [Abstract][Full Text] [Related]
18. TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis. Hu J; Lai Y; Huang H; Ramakrishnan S; Pan Y; Ma VWS; Cheuk W; So GYK; He Q; Geoffrey Lau C; Zhang L; Cho WCS; Chan KM; Wang X; Rebecca Chin Y Br J Cancer; 2022 Jan; 126(1):57-71. PubMed ID: 34718356 [TBL] [Abstract][Full Text] [Related]
19. LncRNA LINC00173 enhances triple-negative breast cancer progression by suppressing miR-490-3p expression. Fan H; Yuan J; Li X; Ma Y; Wang X; Xu B; Li X Biomed Pharmacother; 2020 May; 125():109987. PubMed ID: 32058222 [TBL] [Abstract][Full Text] [Related]
20. BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells. Zhang X; Wang Y; Chiang HC; Hsieh YP; Lu C; Park BH; Jatoi I; Jin VX; Hu Y; Li R Breast Cancer Res; 2019 Apr; 21(1):51. PubMed ID: 30995943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]